Overall, the ruxolitinib cream was safe and well-tolerated. It is estimated that there are over 54 million AD patients in China by 2024. The NDA for vitiligo indication of the Product has been accepted by the National Medical Products Administration of China (NMPA). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States and Europe as Opzelura®. Media ContactBrand: China Medical System Holdings Ltd.